Literature DB >> 32066565

Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.

Yunzhao Chen1,2, Huahua Xin1, Hao Peng1, Qi Shi1, Menglu Li1, Jie Yu2, Yanxia Tian1, Xueping Han1, Xi Chen1, Yi Zheng3, Jun Li4, Zhihao Yang1, Lan Yang1, Jianming Hu1, Xuan Huang5, Zheng Liu5, Xiaoxi Huang5, Hong Zhou6, Xiaobin Cui7, Feng Li7,5.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the deadliest malignant diseases. Multiple studies with large clinic-based cohorts have revealed that variations of phospholipase C epsilon 1 (PLCE1) correlate with esophageal cancer susceptibility. However, the causative role of PLCE1 in ESCC has remained elusive. Here, we observed that hypomethylation-mediated upregulation of PLCE1 expression was implicated in esophageal carcinogenesis and poor prognosis in ESCC cohorts. PLCE1 inhibited cell autophagy and suppressed the protein expression of p53 and various p53-targeted genes in ESCC. Moreover, PLCE1 decreased the half-life of p53 and promoted p53 ubiquitination, whereas it increased the half-life of mouse double minute 2 homolog (MDM2) and inhibited its ubiquitination, leading to MDM2 stabilization. Mechanistically, the function of PLCE1 correlated with its direct binding to both p53 and MDM2, which promoted MDM2-dependent ubiquitination of p53 and subsequent degradation in vitro. Consequently, knockdown of PLCE1 combined with transfection of a recombinant adenoviral vector encoding wild-type p53 resulted in significantly increased levels of autophagy and apoptosis of esophageal cancer in vivo. Clinically, the upregulation of PLCE1 and mutant p53 protein predicted poor overall survival of patients with ESCC, and PLCE1 was positively correlated with p53 in ESCC cohorts. Collectively, this work identified an essential role for PLCE1- and MDM2-mediated ubiquitination and degradation of p53 in inhibiting ESCC autophagy and indicates that targeting the PLCE1-MDM2-p53 axis may provide a novel therapeutic approach for ESCC. SIGNIFICANCE: These findings identify hypomethylation-mediated activation of PLCE1 as a potential oncogene that blocks cellular autophagy of esophageal carcinoma by facilitating the MDM2-dependent ubiquitination of p53 and subsequent degradation. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/11/2175/F1.large.jpg. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32066565     DOI: 10.1158/0008-5472.CAN-19-1912

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Structural studies of antitumor compounds that target the RING domain of MDM2.

Authors:  James Ross Terrell; Sijia Tang; Oluwafoyinsola Omobodunde Faniyi; In Ho Jeong; Jun Yin; Bhavitavya Nijampatnam; Sadanandan E Velu; Wei Wang; Ruiwen Zhang; Ming Luo
Journal:  Protein Sci       Date:  2022-08       Impact factor: 6.993

2.  Identification of a PLCE1‑regulated competing endogenous RNA regulatory network for esophageal squamous cell carcinoma.

Authors:  Zhihao Yang; Yi Hui; Hao Peng; Hongpan Zhang; Menglu Li; Lingxie Song; Feng Li; Xiaobin Cui
Journal:  Oncol Rep       Date:  2021-01-04       Impact factor: 3.906

3.  Inhibition of the Phospholipase Cε-c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties.

Authors:  Masashi Okada; Yurika Nakagawa-Saito; Yuta Mitobe; Asuka Sugai; Keita Togashi; Shuhei Suzuki; Chifumi Kitanaka
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

Review 4.  Epigenetic regulation of autophagy: A key modification in cancer cells and cancer stem cells.

Authors:  Harpreet K Mandhair; Urban Novak; Ramin Radpour
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

5.  CircPLCE1 facilitates the malignant progression of colorectal cancer by repressing the SRSF2-dependent PLCE1 pre-RNA splicing.

Authors:  Zhilei Chen; Hongyu Chen; Lei Yang; Xiangnan Li; Zhenjun Wang
Journal:  J Cell Mol Med       Date:  2021-06-26       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.